편두통치료의 최근발전

문 희 수
성균관대학교 강북삼성병원 신경과

Recent Advances in Treatment for Migraine

Heui-Soo Moon, MD, PhD
Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Advancement in the understanding of migraine pathophysiological mechanisms and identification of potential targets have resulted in a multitude of emerging acute and preventive treatments. Targeting the calcitonin gene-related peptide (CGRP) pathway to treat these headaches may be the first focused therapeutic option to date, with the potential for promising efficacy. Efficacy of anti-CGRP monoclonal antibodies (mAbs) spells a promising future for the many patients suffering from migraine, and possibly also for the smaller but severely-affected population with cluster headache. Four injectable monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). Another emerging agents with novel mechanisms of action that have demonstrated efficacy for the acute treatment of migraine include the small molecule CGRP receptor antagonists (gepants), and a selective serotonin (5-HT1F) receptor agonist (ditans). Unlike triptans and ergotamine derivatives, these novel drugs do not cause vasoconstriction and may have a special role in patients who have contraindications to the use of triptans or who have failed to respond to or tolerate at least 2 oral triptans. In this year, several guidelines in headache field has been issued: the American headache society position statement on integrating new migraine treatments into clinical practice, practice guideline for the acute and preventive treatment of migraine in children and adolescents by American headache society and expert-based guideline on the use of the CGRP mAbs for migraine prevention by The European Headache Federation.

Key Word: Migraine, Treatment, Anti-CGRP monoclonal antibody

Heui-Soo Moon
Department of Neurology, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, 29 Saemunan-Ro,
Jongno-Gu, Seoul, 03181, Korea
Tel: +82-2-2001-2101 Fax: +82-2-2001-2100
E-mail: drmhs0801@gmail.com